| Bioactivity | SL-052 is a hypocrellin-based photosensitizer that has recently shown promising results in clinical and preclinical testing for cancer photodynamic therapy (PDT). SL-052 is encapsulated in biodegradable polylactic-co-glycolic acid (PLGA) polymer nanoparticles optimized using single emulsion solvent evaporation technology. The SL-052-PLGA nanoparticles were more effective in PDT treatment of subcutaneous SCCVII squamous cell carcinoma compared to polyvinylpyrrolidone (PVP)-based and standard liposomal SL-052 formulations. A longer time interval between drug injection and tumor illumination can improve tumor cure rates, and SL-052-PLGA nanoparticles showed the best therapeutic effect among all SL-052 formulations. |
| CAS | 925438-34-2 |
| Formula | C35H32N2O7 |
| Molar Mass | 592.64 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Antitumor Efficacy of Photodynamic Therapy Using Novel Nanoformulations of Hypocrellin Photosensitizer SL052 |
SL-052
CAS: 925438-34-2 F: C35H32N2O7 W: 592.64
SL-052 is a hypocrellin-based photosensitizer that has recently shown promising results in clinical and preclinical test
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.